............................
2015
2014
2013
Archive
............................
Portfolio News
............................
New Leaf News
............................
|
Prometheus Unveils Novel Approach for
Predicting Risk of Disease Progression in Patients with Crohn’s
Disease
San Diego, May 3, 2010 – Prometheus Laboratories Inc., a
specialty pharmaceutical and diagnostic company, announced new
findings supporting a novel, algorithm-based biomarker test that
helps clinicians effectively predict the risk of developing
aggressive disease in patients with Crohn’s disease.
In an oral presentation yesterday at Digestive Disease Week
(DDW) in New Orleans, Dr. Gary Lichtenstein, Professor of
Medicine, Director of the Inflammatory Bowel Disease Program at
the Hospital of the University of Pennsylvania, reported results
from a cross-sectional study in which six serologic markers and
three genetic mutation markers were analyzed to help identify
patients who are at risk for a more severe course of disease
over time.
"There is growing evidence that biomarkers may provide clinical
insight in predicting the probability of progression to an
aggressive disease behavior," said Dr. Lichtenstein. "This study
shows that by combining serologic and genetic (serogenetic)
markers with clinical parameters, disease severity can be
accurately predicted in patients with Crohn’s disease to help
physicians stratify the risk of disease progression and manage
patients more effectively."
About Crohn’s Disease
Crohn’s disease is a chronic disorder that causes inflammation
of the digestive or gastrointestinal tract. Symptoms of the
disease include diarrhea, abdominal pain, fever and rectal
bleeding. Crohn’s disease is often expensive to treat because
many patients may require long-term medical care, including
multiple hospitalizations, surgeries and expensive therapeutics.
The condition can be difficult to manage clinically and consumes
a substantial amount of healthcare resources in terms of
physician time, procedures and medications. Crohn’s disease is
estimated to affect between 400,000 and 600,000 individuals in
North America.
About Prometheus
Prometheus Laboratories Inc. is committed to improving lives
through the development and commercialization of novel
pharmaceutical and diagnostic products that enable physicians to
provide greater individualized patient care. Prometheus is a
leader in applying the principles of personalized medicine to
the diagnosis and treatment of gastrointestinal diseases and is
applying these principles to oncology. Its strategy includes the
marketing and delivery of pharmaceutical products complemented
by proprietary diagnostic testing services. By integrating
therapeutics and diagnostics, Prometheus believes it can provide
physicians with a comprehensive solution to treat chronic
diseases. Prometheus’ corporate offices are located in San
Diego, California.
Contact
Pete De Spain
Director, Investor Relations
& Corporate Communications
Prometheus Laboratories Inc.
(858) 587-4117
pdespain @prometheuslabs.com |